XTL Biopharmaceuticals XTLB Stock
XTL Biopharmaceuticals Price Chart
XTL Biopharmaceuticals XTLB Financial and Trading Overview
| XTL Biopharmaceuticals stock price | 2.26 USD |
| Previous Close | 2.44 USD |
| Open | 2.48 USD |
| Bid | 1.78 USD x 200 |
| Ask | 3.17 USD x 200 |
| Day's Range | 2.39 - 2.5 USD |
| 52 Week Range | 2.12 - 10.28 USD |
| Volume | 17.36K USD |
| Avg. Volume | 1.89M USD |
| Market Cap | 5.68M USD |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
XTLB Valuation Measures
| Enterprise Value | 2.12B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 2.27 |
| Price/Sales (ttm) | 5.865144 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 2185.074 |
| Enterprise Value/EBITDA | N/A |
Trading Information
XTL Biopharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.71 |
| 52-Week Change | -50.00000000000000000000000000000000% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 10.28 USD |
| 52 Week Low | 2.12 USD |
| 50-Day Moving Average | 2.63 USD |
| 200-Day Moving Average | 3.65 USD |
XTLB Share Statistics
| Avg. Volume (3 month) | 1.89M USD |
| Avg. Daily Volume (10-Days) | 27.3K USD |
| Shares Outstanding | 2.37M |
| Float | 274.56M |
| Short Ratio | 0 |
| % Held by Insiders | 38.46% |
| % Held by Institutions | 3.16% |
| Shares Short | 19.22K |
| Short % of Float | 7.83% |
| Short % of Shares Outstanding | 0.80% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -853.57% |
| Gross Margin | -232.85% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -240.56% |
| Return on Equity (ttm) | -577.12% |
Income Statement
| Revenue (ttm) | 968K USD |
| Revenue Per Share (ttm) | 0.4 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -2254000 USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -6308000 USD |
| Diluted EPS (ttm) | -3.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 259K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 86K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.7 |
| Book Value Per Share (mrq) | 0 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of XTL Biopharmaceuticals
| Country | United States |
| State | N/A |
| City | Ramat Gan |
| Address | 26 Ben-Gurion St. |
| ZIP | 5112001 |
| Phone | 972 3 611 6600 |
| Website | https://www.xtlbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Q&A For XTL Biopharmaceuticals Stock
What is a current XTLB stock price?
XTL Biopharmaceuticals XTLB stock price today per share is 2.26 USD.
How to purchase XTL Biopharmaceuticals stock?
You can buy XTLB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for XTL Biopharmaceuticals?
The stock symbol or ticker of XTL Biopharmaceuticals is XTLB.
Which industry does the XTL Biopharmaceuticals company belong to?
The XTL Biopharmaceuticals industry is Biotechnology.
How many shares does XTL Biopharmaceuticals have in circulation?
The max supply of XTL Biopharmaceuticals shares is 2.37M.
What is XTL Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
XTL Biopharmaceuticals PE Ratio is now.
What was XTL Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
XTL Biopharmaceuticals EPS is -3.6 USD over the trailing 12 months.
Which sector does the XTL Biopharmaceuticals company belong to?
The XTL Biopharmaceuticals sector is Healthcare.
XTL Biopharmaceuticals XTLB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}